Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1051/medsci/2020265 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.
Clin Kidney J
January 2025
Department of General Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Stuttgart, Germany.
Background: Sparsentan, a dual-acting antagonist for both the angiotensin II receptor type 1 and the endothelin receptor type A, has emerged as a promising therapeutic agent for the treatment of IgA nephropathy (IgAN). Following the publication of the PROTECT trial, sparsentan recently received approval for the treatment of IgAN in Europe. However, it remains uncertain whether an additive effect can be observed in the context of existing treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors, given that the PROTECT study did not investigate this dual therapy approach.
View Article and Find Full Text PDFReport of a Rare Case of Acute Abdominal Pain Post-partum: Spontaneous Ureteral Rupture.
Cureus
December 2024
Radiology, West Suffolk NHS Foundation Trust, Bury St Edmunds, GBR.
Spontaneous ureteral rupture is a rare cause of acute abdominal pain, particularly unusual during pregnancy or the post-partum period. While pregnancy-related changes like ureteral compression and dilation may play a role, no definitive mechanisms have been established. Clinicians should suspect ureteric injury in post-partum patients with free pelvic fluid.
View Article and Find Full Text PDFNatural flavonoid glycosides Chrysosplenosides I & A rejuvenate intestinal stem cell aging via activation of PPARγ signaling.
Life Med
June 2024
Laboratory of Stem cell and anti-Aging Research, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China.
The decline in intestinal stem cell (ISC) function is a hallmark of aging, contributing to compromised intestinal regeneration and increased incidence of age-associated diseases. Novel therapeutic agents that can rejuvenate aged ISCs are of paramount importance for extending healthspan. Here, we report on the discovery of Chrysosplenosides I and A (CAs 1 & 2), flavonol glycosides from the Xizang medicinal plant Maxim.
View Article and Find Full Text PDFDownregulation of AATK enhances susceptibility to ferroptosis by promoting endosome recycling in gefitinib-resistant lung cancer cells.
J Pathol
January 2025
Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Ferroptosis has been characterised by disruption of the cell membrane through iron-related lipid peroxidation. However, regulation of iron homeostasis in lung cancer cells that are resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) remains unclear. Transcriptome analysis identified a significant downregulation of apoptosis-associated tyrosine kinase (AATK) mRNA expression in gefitinib-resistant PC9 (PC9-GR) cells, which were found to be more susceptible to ferroptosis inducers.
View Article and Find Full Text PDFAnalysis of the potential biological mechanisms of geniposide on renal fibrosis by network pharmacology and experimental verification.
BMC Pharmacol Toxicol
January 2025
Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui, 230601, China.
Background: Renal fibrosis is crucial in the progression of chronic kidney disease (CKD) to end-stage renal failure. Geniposide, an iridoid glycoside, has shown therapeutic potential in acute kidney injury, diabetic nephropathy, and atherosclerosis. The aim of this study was to investigate the role of geniposide in renal fibrosis and its underlying mechanisms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!